Alliance Pharma agrees to £362m acquisition by DBAY
Alliance Pharma has accepted a £362m acquisition offer from DBAY Advisors, increasing the share price from 62.5p to 64.75p, a 3.6% rise. DBAY, which holds a 27.9% stake in Alliance, aims to implement operational changes away from public market pressures. Shareholders will vote on the proposal on 13 March 2025, with completion expected in the first half of 2025, transitioning Alliance to a privately owned entity. Alliance reported a revenue increase to £84m for the first half of 2024, with profit before tax rising to £12.7m.
Pharmaceutical Technology·